IMMX
Immix Biopharma Inc.
$4.33
+$0.31(+7.71%)
67
Overall
60
Value
75
Tech
--
Quality
Market Cap
$47.13M
Volume
382.48K
52W Range
$1.34 - $4.60
Target Price
$8.00
Company Overview
| Mkt Cap | $47.13M | Price | $4.33 |
| Volume | 382.48K | Change | +7.71% |
| P/E Ratio | -2.2 | Open | $3.88 |
| Revenue | -- | Prev Close | $4.02 |
| Net Income | $-21.6M | 52W Range | $1.34 - $4.60 |
| Div Yield | N/A | Target | $8.00 |
| Overall | 67 | Value | 60 |
| Quality | -- | Technical | 75 |
No chart data available
About Immix Biopharma Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Latest News
Immix Biopharma’s NXC-201 CAR-T Study: A Potential Game-Changer for AL Amyloidosis
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMMX | $4.33 | +7.7% | 382.48K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |